Abstract: Two patients with lung cancers presented with cutaneous capillary endothelial proliferation on the head, face, trunk, and extremities after the first treatment with camrelizumab for 2 or 3 weeks. Some lesions which were accompanied with ulceration and bleeding were treated with surgical resections. The histological feature was in accordance with granulomatous hemangioma. The diagnosis of reactive cutaneous capillary endothelial proliferation was made.

Key words: camrelizumab, PD-1 inhibitor, reactive cutaneous capillary endothelial proliferation, Immune-related adverse events